


NGS in diagnostics: where things can go wrong

Johan den Dunnen and Anna Benet-Pagès

VEPTC – Johor 2018

NGS Workflow


- Sampling
- Sample preparation
- Sequencing
- Mapping
- Variant Calling
- Variant Annotation
- Checks
- Variant Interpretation



NGS Workflow

- Sampling
- Sample preparation
- Sequencing
- Mapping
- Variant Calling
- Variant Annotation
- Checks
- Variant Interpretation

Sample Swaps and contamination - frequency and most common reasons



60%

19%

15%

**Molecular genetic testing
88.394 patients , 1 year**

Percentage of laboratory errors by processing phase; *Green, 2013*

- LIMS
- Barcoding
- Double check (2-man rule)
- Automated liquid handling
- Paralell sample identification analysis
(second methodology)
- Programming of system interfaces





Fig. 2. The total cost of specimen rejection can be quantified by cost category.

Sample preparation – PCR-based – regions not amplified


Challenge: Primer design in GC, repeats, SNPs
Consequences: amplicon amplification reproducibility low
allelic drop out
uneven coverage



—■— Region of interest: exons we want to analyze within the panel

—■— Validation: covered regions from the NGS results


Fragment 17, exon length: 733bp, mean cov.: 565.7



—■— coverage of a single amplicon

CNV detection not possible

Sample preparation – capture-based – uneven coverage



chr16:89,574,732-89,575,060 329 bp.

enter position, gene symbol, HGVS or search terms

go

chr16 (q24.3) 16p13.3 16p12.3 16p11.2 16q11.2 16q12.1 16q12.2 16q21 16q22.1 16q23.1

Scale
chr16:

89,574,800|

100 bases|
89,574,850|

89,574,900|

89,574,950|

89,575,000|

89,575,050|

Haplotypes to GRCh37 Reference Sequence

Patches to GRCh37 Reference Sequence

UCSC Genes (RefSeq, GenBank, CCDS, Rfam, tRNAs & Comparative Genomics)

SPG7 MAVLLLLLRALRRGPGGPRPLWGPGPAWSPGFPARPGRGRPYMASRPPGDLAEAGGRALQ

SPG7 MAVLLLLLRALRRGPGGPRPLWGPGPAWSPGFPARPGRGRPYMASRPPGDLAEAGGRALQ

ClinVar Short Variants <= 100bp

A>G
G>A
G>T
G>T
C>T
C>G
G>A
G>A
G>A
G>A
T>C


missed variants

Sample preparation – uneven coverage – false CNV calls

2. SCN1A

Number of exons 26
Duplications in 5 exons and 4 calls (frequency = 0.00)
Deletions in 26 exons and 39 calls (frequency = 0.01)

False positive deletion calls in the *SCN1A* gene




Sample preparation - capture – homologues sequences

VWF gene causes „von Willebrand Syndrom“:


Pathogenic mechanismus: SNVs (~90%), CNVs (~10%), 6-335 bp geneconversions



VWF – von Willebrand factor gene
chr12:6,118,707-6,137,253




VWFP1 - von Willebrand factor pseudogene 1
chr22:17,170,925-17,185,367





Sequencing – systematic errors – occur in 1 in 1000 base pairs

- base-call errors aggregate at specific genomic locations across multiple sequence reads



motiv around systematic errors




Pfeifer et al.; 2018

NGS Workflow

- Sampling
- Sample preparation
- Sequencing
- Mapping
- Variant Calling
- Variant Annotation
- Checks
- Variant Interpretation

reference genome – minor allele - variants missed

- hg19 reference assembly do not represent major alleles at all three billion positions
- 7% of false negative calls and 30% of false positive calls




Hg19	A (minor allele)	A (minor allele)	A (minor allele)
sample	A	A/T	T
call	No call	Call T (major allele)	Call T (major allele)

chr	Nucleotide substitution	Gene	Amino acid substitution	Alternate allele frequency
chr2	g.130949411T>G	TUBA3E	p.(Glu449Ala)	0.020567
chr6	g.29364787T>C	OR12D2	p.(Phe104Ser)	0.021166
chr6	g.33382288A>G	PHF1	p.(Lys304Arg)	0.022364
chr2	g.231149108A>G	SP140	p.(Lys516Glu)	0.026158
chr17	g.37101380C>T	FBXO47	p.(Arg209Gln)	0.027955
chr14	g.24901276T>G	KHNYN	p.(Leu270Trp)	0.040535
chr16	g.1389153A>C	BAIAP3	p.(Thr87Pro)	0.04373
chr19	g.29704010C>A	UQCRCF51	p.(Ala6Ser)	0.046126
chr22	g.22989256G>A	GGTL2	p.(Gly70Glu)	0.046925
chr16	g.1370597C>G	UBE2I	p.(Ser164Arg)	0.049521
chr16	g.1370614G>C	UBE2I	p.(Arg170Thr)	0.049521
chr21	g.37617630G>T	DOPEY2	p.(Gly1118Cys)	0.050719
chr9	g.140130606T>A	SLC34A3	p.(Val513Glu)	0.053914
chr6	g.29141743G>A	OR2J2	p.(Ala111Thr)	0.058506
chr6	g.42666145T>C	PRPH2	p.(Lys310Arg)	0.058706
chr2	g.180810264T>A	CWC22	p.(Arg773Ser)	0.06869
chr17	g.80895933G>A	TBCD	p.(Gly1135Glu)	0.069089
chr2	g.96795857C>T	ASTL	p.(Arg222Gln)	0.072883
chr14	g.36789729G>T	MBIP	p.(Ser22Arg)	0.073083
chr3	g.12046364C>G	SYN2	p.(Pro37Ala)	0.073682
chr6	g.29911256G>T	HLA-A	p.(Glu185Asp)	0.074281
chr11	g.111749349T>A	FDXACB1	p.(Asn87Ile)	0.07528
chr2	g.44104925C>T	ABCG8	p.(Ala632Val)	0.077077
chrX	g.65382685C>T	HEPH	p.(Ala39Val)	0.079205
chr19	g.56047448G>A	SBK2	p.(Arg72Cys)	0.082069
chrX	g.88008423C>A	CPXCR1	p.(Ser31Try)	0.086358
chr19	g.36497358G>C	SYNE4	p.(His278Gln)	0.08726
chrX	g.84563135A>T	POF1B	p.(Leu349Met)	0.087947
chr17	g.72938100C>T	OTOP3	p.(Pro119Ser)	0.09385
chr5	g.741736T>G	ZDHHC11B	p.(Asp314Ala)	0.095248
chr5	g.140559596G>T	PCDH8	p.(Val661Leu)	0.097644
chr1	g.155026942C>A	ADAM15	p.(Thr191Lys)	0.098043
chr1	g.34330067C>A	HMG84	p.(Ala92Glu)	0.098842
chr7	g.150500729G>A	TMEM176A	p.(Ala122Thr)	0.09984

Lists 34 nonsynonymous mutations with allele frequencies <10%. Column 2 represents the nucleotide substitution as per hg19K reference. Column 3 represents the gene in which the mutation lies, and Column 4 gives the corresponding amino acid substitution. Column 5 is the allele frequency for the alleles in hg19.

Hg19 RECQL4 chr8:145738768-145738768




A: 6.250% (1 / 16): C: 6.250% (1 / 16): G: 81.250% (13 / 16): T: 6.250% (1 / 16)

RECQL4 (NM_004260): [missense variant](#) R (CGG) → W (TGG)

This single-base substitution is quad-allelic.

UCSC Genes RECQL4 (uc003zdj.3) splice acceptor variant



Mapping – reference genome – indel errors

- Reference genome (ABO O-type, del 1 nt) and reference transcript differ (ABO A-type)

Reference SNP (refSNP) Cluster Report: rs8176719			**Clinical Channel**
RefSNP		Allele	HGVS Names
Organism:	human (<i>Homo sapiens</i>)	Variation Class: DIV: deletion/insertion variation	CM000671.2:g.133257521_133257522insC
Molecule Type:	Genomic	RefSNP Alleles: -/G (REV)	NC_000009.11:g.136132908_136132909insC
Created/Updated in build:	117/151	Allele Origin:	NC_000009.12:g.133257521_133257522insC
Map to Genome Build:	108/Weight 1	Ancestral Allele: A	NG_006669.1:g.20145_20147insG
Validation Status:		Variation Viewer:	NM_020469.2:c.260_262insG
Citation:	PubMed LitVar ^{NEW}	Clinical Significance: NA	NP_065202.2:p.Val87_Thr88=fs
Association:	NHGRI GWAS	MAF/MinorAlleleCount: C=0.3764/45143 (ExAC) C=0.3438/1722 (1000 Genomes) C=0.3400/4154 (GO-ESP) C=0.3456/43394 (TOPMED)	XP_005276905.1:p.Thr87Aspfs
			XP_005276906.1:p.Thr69Aspfs

Note the strange, non-HGVS, descriptions.
All are incorrect.

Variant: rs8176719

rs8176719 INSERTION

Most severe consequence

Alleles

Location

Evidence status

HGVS names

Synonyms

Original source

About this variant

frameshift variant | See all predicted consequences

-/C | MAF: 0.34 (C) | Highest population MAF: 0.48

Chromosome 9: between 133257521 and 133257522 (forward strand) | VCF: 9 133257521 rs8176719 T TC

This variant has 9 HGVS names - Hide

Ensembl HGVS:

- NC_000009.12:g.133257521_133257522insC
- ENST00000453660.4:n.290_291insG
- ENST00000538324.2:c.259-1_259insG
- ENSP00000483018.1:p.Thr87AspfsTer107
- ENST00000611156.4:c.259-1_259insG
- ENSP00000483265.1:p.Thr87AspfsTer107
- ENST00000647353.1:n.54-6370_54-6369insG

dbSNP HGVS:

- NM_020469.2:c.260_262insG
- NP_065202.2:p.Val87_Thr88=fs

PharmGKB PA166170086


Variants (including SNPs and indels) imported from dbSNP (release 150) | View in dbSNP

This variant overlaps 4 transcripts, has 2550 sample genotypes, is associated with 2 phenotypes and is mentioned in 54 citations.

Ensembl data copied from dbSNP

Mapping variants in simple sequences (homopolymers)

- MSH2 : NM_000251:c.942+3A>T Most frequent pathogenic MSH2 variant in HNPCC – Lynch Syndrome





Mapping – missing insertions

Breast Cancer Res Treat. 2009 Mar;114(1):31-8. doi: 10.1007/s10549-008-9978-4. Epub 2008 Mar 25.


The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.

Peixoto A¹, Santos C, Rocha P, Pinheiro M, Príncipe S, Pereira D, Rodrigues H, Castro F, Abreu J, Gusmão L, Amorim A, Teixeira MR.

➤ BRCA2



Mapping – reference genome – repetitive regions



Mapping non-unique

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

+

+

GATTGGGCAGAGCGATGG

*GATTGGG**T**AGAGCGATGG*

GATTGGGCAGAGCGATGG

*GATTGGG**T**AGAGCGATGG*

Mapping non-unique

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

Non-unique

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

GATTGGGCAGAGCGATGG

Non-unique

GATTTGGGCAGAGCGATGG

GATTTGGGCAGAGCGATGG

GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG

Non-unique

GATTTGGGCAGAGCGATGG

GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*

GATTTGGGCAGAGCGATGG

*GATTTGGG**T**AGAGCGATGG*
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*

Map Non-unique

GATTTGGGCAGAGCGATGG

GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG

GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*
*GATTTGGG**T**AGAGCGATGG*
GATTTGGGCAGAGCGATGG

GATTTGGGCAGAGCGATGG

GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
*GATTTGGG**T**AGAGCGATGG*


GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG
GATTTGGGCAGAGCGATGG

Mapping in pseudogenes – missing SNVs due to Gene conversions

- *Pseudoxanthoma elasticum*; c.4182del (p.Lys1394Asnfs*9) – class 5

ABCC6

exon 9 dosis 0,5





Case

Control

ABCC6P1

exon 9 dosis 1,5



ABCC6

ABCC6P1


Variant Calling – missing SNVs due to Gene conversions



[Journal of Molecular Medicine](#)

September 2001, Volume 79, [Issue 9](#), pp 536–546

A novel *Q378X* mutation exists in the transmembrane transporter protein *ABCC6* and its pseudogene: implications for mutation analysis in pseudoxanthoma elasticum




c.4182del (p.Lys1394Asnfs*9) - class 5


c.1132C>T p.Q378* - class 5

Variant Calling – male/female – X and Y chr pseudoautosomal region


- Number of SNVs called in X and Y chromosome in males



Chromosome Y: 10,001-2,781,479



Region overview



Variant Calling – male/female – X and Y chr pseudoautosomal region

For variant calling, where to draw the line (threshold)


We set it initially at 10 reads or more, i.e. variants are not reported when we had 10 reads or less.

As a consequence we missed 9 reads, all with the same variant, on the X-chromosome in a male patient causing the disease !

A proper NGS pipelines treats the X-/Y- chromosomes different to call variants in males.

Variant Calling – SVs and CNVs – different tools deliver diferent calls

➤ Sample set ~1000 individuals



Tool	Mean Calls per Sample
Canoes	~ 1.4
Clamms	~ 5.1
Codex	~ 2.6
ExomeDepth	~ 7.7
Inhouse	~ 4.4


Variant Calling – limits of detection - mosaicism in PIK3CA

Somatic Mosaic Activating Mutations in *PIK3CA* Cause CLOVES Syndrome


[Kyle C. Kurek](#),¹ [Valerie L. Luks](#),² [Ugur M. Ayturk](#),^{2,9} [Ahmad I. Alomari](#),^{3,6} [Steven J. Fishman](#),^{4,6} [Samantha A. Spencer](#),^{2,6} [John B. Mulliken](#),^{5,6} [Margot E. Bowen](#),^{2,9} [Guilherme L. Yamamoto](#),⁷ [Harry P.W. Kozakewich](#),^{1,6} and [Matthew L. Warman](#)^{2,6,8,9,*}

- Look for the right variant feature in the right gene/disease

Only detected with the
LOW-FREQUENCY pipeline




NM_006218
c.3145G>A:p.Gly1049Ser



NM_006218
c.2740G>A:p.Gly914Arg

Annotation – delins in splice site regions

RASA1 : NM_002890:c.1016_1017insTTA:p.Gly340*; het; AD >>>> Stopp gain




Addition of tyrosin > splice-site not affected (moves 3 positions)

Annotation – delins annotation as two single events

BRCA2 : NM_000059_c.5609T>A;p.Phe1870Tyr;het

BRCA2 : NM_000059_c.5609T>A;p.Phe1870Leu;het



NCBI Resources How To

ClinVar ClinVar Search ClinVar for gene symbols, HGVS Advanced

Home About Access Help Submit Statistics FTP

NEW Click here to see the new Variation Report design!

NM_000059.3(BRCA2):c.5609T>A (p.Phe1870Tyr)

Variation ID: 431319

Review status: (0/4) no assertion criteria provided

Interpretation

Clinical significance: Uncertain significance

Last evaluated: Mar 5, 2014

Number of submission(s): 1

See supporting ClinVar records

NEW Click here to see the new Variation Report design!

NM_000059.3(BRCA2):c.5610C>G (p.Phe1870Leu)

Variation ID: 441502

Review status: criteria provided, single submitter

Interpretation

Clinical significance: Uncertain significance

Last evaluated: Oct 11, 2016

Number of submission(s): 1

Condition(s): Hereditary cancer-predisposing syndrome [MedGen]

Annotation – delins annotation as two single events

BRCA2 : NM_000059_c.5609T>A;p.Phe1870Tyr;het

BRCA2 : NM_000059_c.5609T>A;p.Phe1870Leu;het

41 bp

32,914,090 bp

32,914,100 bp

← → ↺ 🏠

Meistbesucht Erste Schritte Amazon.de Einkaufsw... Befunde - Befundverw... Befunde - Dashboard ...

e!Ensembl BLAST/BLAT | VEP | Tools | BioMart | Downloads | Help & Docs | Blog

Using this website Annotation and prediction Data access **API & software** About us

In this section

On this page

- REST API
- Download and install

Haplosaurus

HGVS: BRCA2: c.5609_5610delTCinsAG (p.Phe1870*)

Type	Gene	MOI	Changes	Tag	Position	Ref	Alt	GT	VAF	rsID
syn	BRCA2	AD, SMu, AR	NM_000059:c.6513G>C;p.Val2171Val	-	chr13:32915005-32915005	G	C	hom	-	rs206076
non_syn	BRCA2	AD, SMu, AR	NM_000059:c.7397T>C;p.Ala2466Ala	-	chr13:32929387-32929387	T	C	hom	-	rs169547
intron	BRCA2	AD, SMu, AR	NM_000059:c.7806-14T>C	-	chr13:32936646-32936646	T	C	het	-	rs9534262
utr3_pr	BRCA2	AD, SMu, AR	NM_000059:c.*369A>G	-	chr13:32973276-32973276	A	G	het	-	rs7334543
non_syn	BRCA2	AD, SMu, AR	NM_000059:c.5609T>A;p.Phe1870Tyr	-	chr13:32914101-32914101	T	A	het	-	
non_syn	BRCA2	AD, SMu, AR	NM_000059:c.5610C>G;p.Phe1870Leu	-	chr13:32914102-32914102	C	G	het	-	

NCBI Resources How To

ClinVar ClinVar Search ClinVar for gene symbols, HGVS

Advanced

Home About Access Help Submit Statistics FTP

NEW Click here to see the new Variation Report design!

A (p.Phe1870Tyr)

(0/4) no assertion criteria provided

in significance

2014

n Report design!

(p.Phe1870Leu)

02

criteria provided, single submitter

Interpretation ?


Clinical significance: [Uncertain significance](#)

Last evaluated: Oct 11, 2016

Number of submission(s): 1

Condition(s): Hereditary cancer-predisposing syndrome [\[MedGen\]](#)

Filtering after population frequency = missed variant in complex call event



PKHD1

NM_138694:c.12142C>T:p.Gln4048*

➤ truncating strong

NM_138694:c.12141A>G:p.Gln4048Arg hom

➤ >5% frequency (automatically filtered out)



NGS Workflow

- Sampling
- Sample preparation
- Sequencing
- Mapping
- Variant Calling
- Variant Annotation
- Checks
- Variant Interpretation

Checks – % mapped reads/ average coverage / target coverage

- Duplicates decrease the efficiency of sequencing



- SSXT 1μg DNA / 390bp frag.size
- SSXT-low input 100ng/ 390bp DNA fragment
- SSXT-low input 100ng/ 430bp DNA fragment
- SSXT-low input 200ng/ 455bp DNA fragment




- Define a minimal coverage threshold in addition to mean coverage

Check - sample contamination


- Check calls: Homozygote vs. heterozygote SNPs/Indels or Transversions vs. Transitions
- Check mapping : reads from other species






Checks – Exclusion of sample swap




NGS raw data
SNPs



Other methodology
SNPs




Checks – new pipeline / component : re-run standard controls



Contents

1. What are the GATK Best Practices?
2. Analysis phases
3. Experimental designs
4. Workflow scripts provided as reference implementations
5. Scope and limitations
6. What is *not* GATK Best Practices?
7. Beware legacy scripts



✓ Best Practices

☑ Introduction to the GATK Best Practices

Best Practices Workflows | Created 2018-01-09 | Last updated 2018-01-09

NGS Workflow

- Sampling
- Sample preparation
- Sequencing
- Mapping
- Variant Calling
- Variant Annotation
- Checks
- Variant Interpretation

Imprinting – maternal vs. paternal inheritance

- Paraganglioma and pheochromocytoma upon maternal transmission of *SDHD* mutations
- Only individuals who inherit the mutation from their father are affected
- If the mutation was inherited from the mother, they are not affected

Paraganglioma and pheochromocytoma upon maternal transmission of *SDHD* mutations

Jean-Pierre Bayley,[✉] Rogier A Oldenburg, Jennifer Nuk, Attje S Hoekstra, Conny A van der Meer, Esther Korpershoek, Barbara McGillivray, Eleonora PM Corssmit, Winand NM Dinjens, Ronald R de Krijger, Peter Devilee, Jeroen C Jansen, and Frederik J Hes

[Author information](#) ► [Article notes](#) ► [Copyright and License information](#) ► [Disclaimer](#)

This article has been [cited by](#) other articles in PMC.

Abstract

[Go to:](#)


Background

[Go to:](#)

The *SDHD* gene encodes a subunit of the mitochondrial tricarboxylic acid cycle enzyme and tumor suppressor, succinate dehydrogenase. Mutations in this gene show a remarkable pattern of parent-of-origin related tumorigenesis, with almost all *SDHD*-related cases of head and neck paragangliomas and pheochromocytomas attributable to paternally-transmitted mutations.

Succinate dehydrogenase D (maternally imprinted, paternally inherited)


□ ○ Male, female



Interpretation – male / female different phenotypes


KIAA2022 – X-linked

Females (epileptic encephalopathy) / males (intellectual disability)



Interpretation – unexpected pathomechanismus

PCDH19: X-linked ... but ONLY heterozygous females and mosaic males are affected



* 300460

PROTODADHERIN 19; PCDH19

Alternative titles; symbols

KIAA1313

HGNC Approved Gene Symbol: **PCDH19**

Cytogenetic location: **Xq22.1** Genomic coordinates (GRCh38): **X:100,291,643-100,410,272** (from NCBI)

Gene-Phenotype Relationships


Location	Phenotype	Phenotype MIM number	Inheritance	Phenotype mapping key
Xq22.1	Epileptic encephalopathy, early infantile, 9	300088	XL	3

Interpretation softwares - Filtering intronic variants nearby exon sites???

- check for default filtering parameters, usually +/-2 !!

>10.000 Samples

6346 variants at the Cartegni site



„Guidelines for Splicing Analysis in Molecular Diagnosis Derived from a Set of 327 Combined *In Silico/In Vitro* Studies on *BRCA1* and *BRCA2* Variants" Tosi, Houdayer, Stoppa-Lyonnet et al. *Hum Mutat* 2013.

Interpretation – keep looking for the second hit!!

➤ IHC loss of MLH1/PMS2 in the tumour


➤ SNV analysis:

heterozygous SNV in MLH1 exon 8
NM_000249.3:c.799G>A+c.800T>G:p.Val267Arg

➤ CNV analysis: inconspicuous

➤ Deep-intronic sequencing:

Complex rearrangement on chromosome 2 that causes a paracentric inversion between the *DCLK3* gene and *MLH1*



Murphys law also apply for diagnostics!!!

